Anuh Pharma Limited

ANUHPHR6

INE489G01022

Pharmaceuticals

Delayed Bombay S.E. Other stock markets 03:30:57 14/06/2024 pm IST			5-day change	1st Jan Change
232.3 ^INR	+0.58%		+3.22%	+58.46%

31/05	Anuh Pharma Limited signed an agreement to acquire 10% stake in Huoban Energy 5 Private Limited from Huoban Private Limited for approximately INR 11.6 million.	CI
17/05	Anuh Pharma Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2024	CI

Anuh Pharma Ltd. Announces Demise of Jayantilal P. Shah as Non-Executive Director

January 11, 2016 at 01:08 pm IST

Anuh Pharma Ltd. announced that Shri. Jayantilal P. Shah, non-executive director (promoter director) of the company has passed away on January 09, 2016. Shri.

Jayantilal P. Shah provided invaluable advice and guidance to the company. His contribution will be missed by the Employees, Management and Board of the company.

Latest news about Anuh Pharma Limited

Anuh Pharma Limited signed an agreement to acquire 10% stake in Huoban Energy 5 Private Limited from Huoban Private Limited for approximately INR 11.6 million.	31/05	CI
Anuh Pharma Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2024	17/05	CI
Anuh Pharma Limited Recommends Dividend for the Financial Year Ended 31 March 2024	17/05	CI
Anuh Pharma Limited Approves Final Dividend for the Financial Year Ended 2022-2023	08/04	CI
Anuh Pharma Limited Appoints Manan Jayesh Vadhan as Company Secretary and Compliance Officer	04/04	CI
Anuh Pharma Limited Announces Completion of Tenure of Jasvantlal Girdharlal Shah as Independent Director	01/04	CI
Anuh Pharma Gets European Regulator's Nod for Anti-Malarial Drug	28/02	MT
Anuh Pharma Limited Announces Resignation of Jinal Dharmil Mehtalia as Company Secretary and Compliance Officer, Effective 14 February, 2024	12/02	CI
Anuh Pharma Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023	09/02	CI
Anuh Pharma Limited Announces the Resignation of Hemant Aunt as Company Secretary and Compliance Officer	11/01	CI
Anuh Pharma Limited Announces Appointment of Ms. Jinal Ajay Shah as Company Secretary and Compliance Officer, Effective from 15 January 2024	05/01	CI
Anuh Pharma Limited Approves the Board Appointments	13/12	CI
Anuh Pharma Limited Approves Board Appointments	10/11	CI
Anuh Pharma Limited Approves Board Appointments	19/23/19	CI
Anuh Pharma Limited Reports Earnings Results for the First Quarter Ended June 30, 2023	11/23/11	CI
Anuh Pharma Limited Reports Earnings Results for the Fourth Quarter Ended March 31, 2023	19/23/19	CI
Anuh Pharma Limited Reports Earnings Results for the Full Year Ended March 31, 2023	19/23/19	CI
Anuh Pharma Limited Announces Board Changes	19/23/19	CI
Anuh Pharma Limited Recommends Final Dividend for the Financial Year Ended 31 March 2023	19/23/19	CI
Anuh Pharma Limited Announces Resignation of Lalitkumar P Shah as Non-Executive Director	10/23/10	CI
Anuh Pharma Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2022	10/23/10	CI
Anuh Pharma Limited Approves Appointment of Hemant Auti as the Company Secretary & Compliance Officer	06/23/06	CI
Anuh Pharma Limited Announces Resignation of Bharat Gangani as Company Secretary and Compliance Officer	20/22/20	CI
Anuh Pharma Limited Approves Final Dividend for the Financial Year Ended 2021-2022	06/22/06	CI
Anuh Pharma Limited Reports Earnings Results for the First Quarter Ended June 30, 2022	05/22/05	CI

Anuh Pharma Limited is an India-based bulk drug manufacturing company. The Company is engaged in the business of manufacturing active pharmaceutical ingredients (API). The Company manufactures Macrolides, Anti-TB, Anti-Bacterials, Anti-Malarial, Anti-Hypertension, Expectorant and Corticosteroids products. Its Macrolides products include Erythromycin, Erythromycin Ethyl Succinate, Erythromycin Stearate, Erythromycin Estolate, Erythromycin Propionate, Erythromycin Phosphate, Erythromycin 11,12 Carbonate and Azithromycin. Its Anti-TB products include Pyrazinamide and Isoniazid. Its Anti-Malarial products include Sulfadoxine and Pyrimethamine. Anti-Bacterials products include Chloramphenicol and Chloramphenicol Palmitate. Anti-Hypertension products include Losartan Potassium, Telmisartan and Atorvastatin Calcium. Its Expectorant product includes Ambroxol Hydrochloride. Its Quinolones product includes Moxifloxacin Hydrochloride.

Sector

Pharmaceuticals

Calendar

09/08/2024 - Q1 2025 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Generic Pharmaceuticals

	1st Jan change	Capi.
ANUH PHARMA LIMITED	+58.46%	139M
SUN PHARMACEUTICAL INDUSTRIES LTD.	+20.37%	43.54B
OTSUKA HOLDINGS CO., LTD.	+18.30%	21.78B
SANDOZ GROUP AG	+19.22%	15.38B
CIPLA LIMITED	+25.55%	15.12B
ZYDUS LIFESCIENCES LIMITED	+60.99%	13.36B
THE MEDICINES COMPANY	-0.05%	6.79B
ONO PHARMACEUTICAL CO., LTD.	-14.84%	6.38B
STADA ARZNEIMITTEL	-8.87%	5.73B
ASPEN PHARMACARE HOLDINGS LIMITED	+8.17%	5.32B